Poor graft function (PGF) is a severe complication of haematopoietic stem cell transplantation (HSCT) and administration of donor stem cell boosts (SCBs) represents a therapeutic option. We report 50 paediatric patients with PGF who received 61 boosts with CD34 + selected peripheral blood stem cells (PBSC) after transplantation from matched unrelated (n = 25) or mismatched related (n = 25) donors. Within 8 weeks, a significant increase in median neutrophil counts (0Á6 vs. 1Á516 9 10 9 /l, P < 0Á05) and a decrease in red blood cell and platelet transfusion requirement (median frequencies 1 and 7 vs. 0, P < 0Á0001 and <0Á001), were observed, and 78Á8% of patients resolved one or two of their cytopenias. 36Á5% had a complete haematological response. Median lymphocyte counts for CD3 + , CD3 + CD4 + , CD19 + and CD56 + increased 8Á3-, 14Á2-, 22.-and 1Á6-fold.
Summary
Poor graft function (PGF) is a severe complication of haematopoietic stem cell transplantation (HSCT) and administration of donor stem cell boosts (SCBs) represents a therapeutic option. We report 50 paediatric patients with PGF who received 61 boosts with CD34 + selected peripheral blood stem cells (PBSC) after transplantation from matched unrelated (n = 25) or mismatched related (n = 25) donors. Within 8 weeks, a significant increase in median neutrophil counts (0Á6 vs. 1Á516 9 10 9 /l, P < 0Á05) and a decrease in red blood cell and platelet transfusion requirement (median frequencies 1 and 7 vs. 0, P < 0Á0001 and <0Á001), were observed, and 78Á8% of patients resolved one or two of their cytopenias. 36Á5% had a complete haematological response. Median lymphocyte counts for CD3 + , CD3 + CD4 + , CD19 + and CD56 + increased 8Á3-, 14Á2-, 22.-and 1Á6-fold.
The rate of de novo acute graft-versus-host disease (GvHD) grade I-III was only 6% and resolved completely. No GvHD grade IV or chronic GvHD occurred. Patients who responded to SCB displayed a trend toward better overall survival (OS) (P = 0Á07). Thus, administration of CD34 + selected
SCBs from alternative donors is safe and effective. Further studies are warranted to clarify the impact on immune reconstitution and survival.
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The therapeutic use of haematopoietic stem cell transplantation (HSCT) from matched unrelated or full haplotype mismatched related donors has been extended in recent years to a wide range of malignant and non-malignant diseases. Poor graft function (PGF) after HSCT is a relevant complication and is defined as at least bilinear severe cytopenia, and/or transfusion requirement, which occurs in a situation of full donor chimerism (thus differentiating from graft rejection) in the absence of disease relapse and severe acute or chronic graft-versus-host disease (aGvHD or cGvHD) (Stasia et al, 2014) . Frequencies from 1% to 27% have been reported and the occurrence of PGF is associated with a high mortality rate due to severe infections and bleeding (Larocca et al, 2006; Olsson et al, 2013; Stasia et al, 2014) . Several factors influence the development of PGF: Underlying disease, donor type, degree of human leucocyte antigen (HLA)-matching, ABO incompatibility, intensity of conditioning, stem cell dose and source, prior GvHD, infections, exposure to myelotoxic drugs and others (Stasia et al, 2014) . Treatment options for PGF include use of growth factors, such as granulocyte colony-stimulating factor (G-CSF), erythropoietin and thrombopoietin (Bittencourt et al, 2005; Poon et al, 2013) , re-transplantation (Remberger et al, 2011) , and stem cell boost (SCB) infusion (Stasia et al, 2014; Larocca et al, 2006; Remberger et al, 1998) .
These approaches have advantages and limitations: growth factors administration is easy to perform but often does not induce a long-lasting response, while performing a second HSCT carries the risk of cumulative toxicity and increased non-relapse mortality (NRM). Induction of GvHD is a concern when using SCBs. Options to reduce the risk of GvHD are to administer another pharmacological immune suppression after boosting (Remberger et al, 1998) or to perform ex vivo T-cell depletion of the SCBs.
Various graft manipulation procedures are currently available and are of high importance, especially for mismatched donors. Options include CD133 + or CD34 + positive selection of donor peripheral blood stem cells (PBSC) and, as recently reported, the use of CD3 + or TcRab T-cell depletion (R adestad et al, 2014) . Here, we report on our single centre experience with CD34 + selected SCB from alternative donors (matched unrelated and mismatched, haploidentical related) for PGF treatment over a 15-year period. Endpoints of this retrospective study were the evaluation of haematopoietic recovery, incidence of GvHD and survival analysis of the patients receiving SCB.
Methods

Patients
A cohort of 50 patients, who underwent HSCT between 1999 and 2015 at T€ ubingen University Children's Hospital, were analysed. Clinical data were collected from patients' clinical documentation. All patients (or parents/legal representatives) gave written informed consent to data use before start of stem cell transplantation. All authors had access to primary data.
Clinical characteristics are summarized in Table I . Median age at transplantation was 11Á8 years (0Á33-38Á4), median body weight (bw) at HSCT was 33 kg (3Á7-89Á1). The most common underlying diseases were acute lymphatic leukaemia (ALL, 46%), acute myeloid leukaemia (AML, 22%) and, regarding non-oncological disease, severe aplastic anaemia (SAA, 10%). Twelve patients (29%) with malignant disease were not in remission at HSCT. 50% received a graft from a matched-unrelated donor (MUD), 50% received a mismatched-related (MMRD) HSCT either from their mother (22%), father (24%) or a sibling (4%). Donor's median age at HSCT was 40 years (21-66).
The myeloablative conditioning regimens were based either on total body irradiation (TBI, 6 fractions of 2 Gy each, n = 19, 38%) or busulfan (16 mg/kg for age >3 years and 20 mg/kg for age <3 years, n = 6, 12%), melphalan (140 mg/m 2 , n = 17, 34%) with specific modifications according to patients' pre-treatment. Serotherapy was carried out with rabbit anti-thymocyte globulin (either ATG F, Fresenius Kabi AG, Bad Homburg, Germany, or ATG, Genzyme, Cambridge, Massachusetts, USA) or with mouse anti-CD3 antibody, Orthoclone OKT3, Janssen-Cilag, Raritan New Jersey, USA (7 patients). Five patients (9Á2%) had rejected their grafts and received an immunoablative, total lymphoid irradiation-based reconditioning regimen and stem cell grafts from a second haploidentical donor as previously described (Lang et al, 2008) .
Definition of poor graft function PGF was defined as (i) at least bilinear cytopenia (Hb < 80 g/l, neutrophil count <1Á0 9 10 9 /l, platelet count <20 9 10 9 /l) and/or (ii) dependence on transfusion, with full-donor chimerism and absence of disease relapse and grade III-IV aGvHD. In case of a HLA mismatched donor, patients were screened for anti-HLA donor-specific antibodies prior to stem cell transplantation. Erythrocyte and platelet auto antibodies were repeatedly tested, thereby excluded these as a cause of the respective cytopenia.
Thirty-four out of 61 SCB (56%) were administered for trilinear cytopenia; 25 (41%) for bilinear cytopenia and 2 (3%) for monolinear involvement.
Boost infusion
A total of 61 SCB were given to 50 patients. Eight patients received more than one boost (range 2-4). Stem cells were isolated from the original donor through leukapheresis. PBSC were mobilized by administration of 10 lg/kg of G-CSF daily for 5 days and were harvested by a single leukapheresis procedure. CD34
+ stem cells were selected by using the automated CliniMACS device (Miltenyi Biotec Bergisch Gladbach, Germany). The cell suspension was infused within a 5 min of processing, via a central venous catheter. All the patients had full donor chimerism prior to SCB. They received either freshly isolated (54%) or cryopreserved (46%) stem cells. No conditioning was performed prior and no immunosuppressive therapy was administered post SCB infusion.
Chimerism
Haematopoietic chimerism characterization was performed on peripheral blood leucocytes by short tandem repreat (STR) polymerase chain reaction with fluorescently marked primers and fragment length analysis through capillary electrophoresis (Wiilasch et al, 2007) .
Response evaluation
As for descriptive statistical analysis, the absolute neutrophil count (ANC) and number of infused blood products (red blood cell and platelet concentrates) per patient before each boost (time point 0, TP0) were compared with the corresponding values 4 weeks (TP1) and 8 weeks (TP2) after SCB.
Patients were classified as "independent from transfusions" when they had not received any blood product within 4 weeks prior to our investigation time points. To ensure that patients had reached a sustained independence from transfusions, they were observed for an additional 4 weeks after TP2.
Moreover, an analysis of lymphocyte subsets recovery was performed: the absolute counts of CD3, CD4, CD8, CD19 and CD56 positive cells, detected by flow cytometry analysis of whole blood at TP0, TP1 and TP2 were compared for each patient. To exclude that lymphocytes had already increased before SCB infusion, an additional time point 4 weeks prior to TP0 was analysed. Lineage specific recovery, or resolution of cytopenia, was defined as ANC ≥ 1Á0 9 10 9 / l for granulocytopenia, no administration of red blood cell transfusion in the preceding 4 weeks before TP1 and/or TP2 for anaemia and no administration of platelet concentrates in the preceding 4 weeks before TP1 and/or TP2 for thrombocytopenia.
As for univariate and survival analysis, when SCB was administered because of trilinear or bilinear involvement, a complete response (CR) was defined as a trilinear or bilinear recovery, respectively, a partial response (PR) was defined as bilinear or monolinear recovery, respectively, and nonresponse (NR) meant no resolution of any of the cytopenias, at each time point. To ensure that patients had reached a sustained independence from transfusions, they were observed for an additional 4 weeks interval after TP2. For statistical tests, the probability of any response (either CR or PR) was compared with NR.
The definition of CR and PR could be applied only to SCB given for at least a bilinear cytopenia. For patients with monolinear involvement, only CR and NR were applicable. Eligibility criteria for evaluation were the availability of blood cell counts and transfusions data at each time point.
GvHD
GvHD was defined according to the Glucksberg criteria (Glucksberg et al, 1974) .
Statistical analysis
For descriptive statistics, continuous variables were analysed using the Mann-Whitney test or Wilcoxon test for ranks. The chosen significance level was a = 0Á05.
Categorical variables were compared using chi-square test or Fisher's exact test.
Kaplan-Meier's method was used to estimate overall survival (OS). Day of HSCT was considered as day 0.
Relapse, lethal infections and death due to other causes were defined as events.
Survival curves were compared through log-rank test. When calculating the cumulative incidence (CI) of NRM, the competing risk was relapse-related mortality.
All analyses were performed with Graph Pad Prism Statistical software, version 7 (GraphPad Software Inc., La Jolla, CA, USA).
Results
Composition and time of stem cell boost infusions
Median time between HSCT and infusion of the 61 SCBs was 94 days (13-519). Grafts contained a median number of 3Á15 9 10 6 CD34 + progenitor cells/kg bw (range 0Á71-27Á9 9 10 6 ) with a median number of 2Á417/kg (range 100-23 630) residual CD3 + T cells.
Lineage specific haematological recovery Neutrophils. Data regarding ANC was available for all except two SCBs (n = 59) in 49 patients. The ANC course after SCB infusion is shown in Fig 1A . Median values were 0Á6 9 10 9 /l at TP 0 and significantly increased to 1Á595 9 10 9 /l and 1Á516 9 10 9 /l at TP1 and TP2, respectively (P < 0Á001 and P < 0Á05). SCBs resulted in an ANC increase after 4 and 8 weeks in 74% and 64% of the procedures.
Transfusion-requiring anaemia. Data were available for 53 SCBs given in 47 patients with an initial requirement for red blood cell transfusions. Transfusion requirement significantly decreased, from a median value of 4 at TP0 to 3 and 1 after 4 and 8 weeks, respectively ( Fig 1B, <0Á0001 in both cases). The decrease occurred in 79Á2% (TP1) and 80Á3% (TP2) of the procedures. Moreover, 24Á5% and 47% resulted in independence from transfusion until TP1 and TP2, respectively. The response was permanent in all cases.
Transfusion-requiring thrombocytopenia. Data were available for 53 SCBs given in 47 patients with an initial requirement for platelet transfusions. Transfusion requirement significantly decreased from a median value of 7 at TP0 to 3 and 0 after 4 and 8 weeks, respectively (Fig 1C, P < 0Á0001 and <0Á001). The decrease occurred in 73Á6% (TP1) and 86Á3% (TP2) of the procedures. Moreover, 21% and 58Á8% resulted in independence from transfusion until TP1 and TP2, respectively. The response was permanent in all but one patient for the following 4 weeks.
Probability of haematological recovery according to number of involved lineages
Next, we investigated whether the number of initially involved lineages influenced the probability of haematological recovery. Patients who had two lines involved achieved a complete (bilinear) recovery in 54Á5% of the procedures, whereas patients with initial trilinear involvement had a complete (trilinear) recovery in 25%. However, this difference was not significant (P = 0Á136). The subgroup of Lineage-specific recovery after stem cell boosting. (A) Increase in neutrophil count (all evaluable stem cell boosts, n = 59), (B) decrease in red blood cell transfusions (only SCBs given for initial transfusion requirement, n = 53), (C) decrease in platelet transfusions (only evaluable SCBs administered for initial platelet transfusion requirement, n = 53). Significance is shown as a continuous straight line, *P < 0Á05, **P < 0Á05 and >0Á001, ***P < 0Á001 and >0Á0001, ****P < 0Á0001). TP0, time point 0 [stem cell boost (SCB) administration]; TP1, time point 1 (4 weeks after SCB); TP2, time point 2 (8 weeks after SCB).
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Recovery of lymphocyte subsets CD3 + and CD19 + lymphocytes showed a constant and significant increase from a median value of 0Á019 9 10 9 /l and 0Á039 9 10 9 /l at TP0 to 0Á067 9 10 9 /l and 0Á039 9 10 9 /l at TP1 (P < 0Á01 for both) and 0Á161 9 10 9 /l and 0Á078 9 10 9 / l at TP2 (P < 0Á001 for both), respectively (Fig 2) . Natural killer (NK) cells rose significantly until TP1 and then reached a plateau (median values: 0Á13 9 10 9 /l at TP0, 0Á199 9 10 9 /l at TP1, 0Á218 9 10 9 /l at TP2) (P < 0Á01). 
CD56
+ cell counts increased after 84Á6%, 82% and 94Á8% of the procedures, respectively. Interestingly, we did not observe any significant increase in the lymphocyte subsets in the 4 weeks preceding SCB administration. This supports our assumption that the improvement in lymphopoiesis was due to the SCBs and not an already ongoing process.
Response assessment
Haematological response was evaluated according to the definitions reported in the methods section. Four weeks after SCB, either a CR or PR was observed in 66% of the procedures. Eight weeks after SCB, the percentage of responses reached 78Á8% and became even more profound, as the CR rate increased from 12Á5% to 36Á5%. Non-response was observed in 34% of procedures 4 weeks after SCB and in 21Á2% of procedures 8 weeks after SCB (Fig 3) .
Response-influencing factors
Donor age at HSCT was the only factor affecting the probability of response to SCB. In detail, patients with donors aged below the median (40 years) had a significantly higher probability of producing any response to SCB at both TP1 and TP2 (P = 0Á038 and P = 0Á004, respectively), whereas gender, age, underlying diagnosis (malignant versus nonmalignant disease), remission status prior to HSCT (for patients with malignant disease), type of conditioning regimen (TBI-based versus non TBI-based), CD34 + cell dose (< vs. > different cut-off values, namely 2, 3, 3Á1, 3Á2, 3Á5, 4, 5, 6, 6Á5, 7, 8, 9, 10, 15 9 10 6 cells/kg bw) did not influence the probability of achieving any response at TP1 and TP2.
Influence of CD34 + cell dose
In those patients who showed a response (either at TP1, TP2 or both, n = 62) the interquartile interval for CD34 + cell dose was 2Á08-6Á35 9 10 6 /kg with a median value of 3Á30 9 10 6 /kg (range 0Á71-27Á9). Patients who did not show any response, either at TP1 or at TP2 (n = 5), received a median CD34 + cell dose of 2Á51 9 10 6 cells/kg (range 1Á0-3Á23, interquartile interval 1Á69-3Á15; Fig 4A) . There was no significant difference in the infused CD34 + cell dose between responders and non responders (P = 0Á39, Mann-Whitney test). Figure 4B shows the differential increase in ANC (defined as ANC at TP2 minus ANC prior to SCB) as a function of given CD34 + cell dose. A trend line indicates that escalating CD34 + cell doses initially lead to a stronger improvement in neutrophil counts. However this effect occurred only up to a certain CD34 + cell dose; for higher values, no further remarkable increase in neutrophil counts could be observed. Although regression analysis did not lead us to a satisfactory description of the relationship between the two variables, we could identify a threshold for CD34 + cell dose for which a stronger effect size (neutrophil increase) occurred. MannWhitney tests for different cut-off values showed significance for values above 3Á25 9 10 6 cells/kg.
GvHD
De novo grade I-III aGvHD occurred in 3 out of 50 patients (6%), while in 1 patient (2%) a pre-existing GvHD worsened after SCB. We observed a complete resolution of all cases of aGvHD, and no chronic GvHD occurred.
Survival
Median follow-up after SCB was 413 days (range 4-5724).
Median follow-up after HSCT was 630 days (range 52-5740).
Of the 50 patients, 29 (58%) died and 21 (42%) survived. Death was related to relapse in 14 patients (28% of total) Recovery of lymphocyte subsets (logarithmic increase of the absolute count). Significance is shown as a continuous straight line, *P < 0Á05, **P < 0Á05 and >0Á001, ***P < 0Á001 and >0Á0001. TP0, time point 0 (stem cell boost [SCB] administration); TP1, time point 1 (4 weeks after SCB); TP2, time point 2 (8 weeks after SCB)
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+ stem cell boosts in paediatric patients ª 2017 John Wiley & Sons Ltd and NRM occurred in 12 (24%) (infections, n = 9; post-HSCT undefined cardiomyopathy, n = 1; multi-organ failure, n = 2). In 3 patients the cause of death was unknown. Among infections, 4/9 had a proven viral aetiology, 3/9 had bacterial sepsis and 1 patient had a fungal infection. In one case the pathogen could not be identified. The current 5-year overall survival (OS) rate of the entire cohort was 38Á67%. We observed a trend towards better OS for patients who had a complete response to SCBs at TP2 compared to non responders (P = 0Á07), while no significant differences were observed for event-free survival (EFS) and cumulative incidence of NRM. However, the subgroup of non-responding patients was too small to draw firm conclusions.
Discussion
We report here 50, mostly paediatric, patients who underwent HSCT from matched unrelated or mismatched related donors and received CD34 + positive-selected SCBs because of PGF. We aimed to analyse whether SCB administration from the original donor, without prior conditioning and without subsequent immunosuppression is safe in terms of GvHD induction and effective in enhancing myeloid recovery. Furthermore, we analysed the impact of SCB on lymphocyte recovery and on patients' survival. Lineage-specific recovery of all 3 myeloid cell lines could be improved. Our analysis showed a significant increase of neutrophil counts or a significant decrease in transfusion requirement for red blood cells or platelets in 64%, 80Á3% and 86Á3% of the procedures, respectively. Although no linear correlation between infused CD34 + cell dose and differential increase of neutrophils was found, we could identify a threshold for which a stronger effect size occurred: infusion of values above 3Á25 9 10 6 /kg CD34 + cells resulted in an optimal increase of neutrophils. For higher values, no further remarkable increase could be observed. Moreover we evaluated the probability of the overall haematological response and factors of influence. The observed response rates (78Á8% of CR or PR 8 weeks after SCB) are comparable with the reported values for adults, although response assessment modalities and duration of haematological follow-up vary considerably among the existing studies, making a comparison difficult. In detail, reported overall response rates were 83% (Stasia et al, 2014) , 81% 4 weeks after SCB (Klyuchnikov et al, 2014) and 72% at +200 days (Askaa et al, 2014) . Younger donor age at HSCT (<40 years) had a significant impact on the probability of response to SCB, whereas all other investigated factors (age at HSCT, gender, underlying diagnosis, remission status at HSCT, type of conditioning regimen, infused CD34 + cell dose) did not have an influence. There is evidence that advanced donor age affects the yield of peripheral stem cells mobilization (Martino et al, 2006) and can be associated with inferior outcome after allogeneic HSCT (Kollman et al, 2001) . Our data support the assumption that similar effects on engraftment and efficacy of SCB exist. Notably, in the present study we analysed only matched unrelated or haploidentical stem cell donors in equal portions, without any matched sibling donors. Despite this fact, the observed de novo aGvHD grade I-III incidence was extremely low (6%) when compared to previously published reports that included matched sibling donors [15% grade II (Stasia et al, 2014) , 17% grade II-IV (Klyuchnikov et al, 2014) , 70% grade I-II (Larocca et al, 2006) , 0% grade III-IV, 22% grade I-IV (Askaa et al, 2014) ]. Although no further immunosuppressive therapy was administered, no cGvHD occurred. This may be explained by the profound T-cell depletion in our SCBs, resulting in a median number of only knowledge, an impact of SCB on immune recovery has not been described so far. In our experience, a fast reconstitution of B and NK cells occurred also after primary transplantation of CD34 + selected stem cells from matched unrelated or mismatched related donor, whereas recovery of T cells was delayed and reached ≥0Á1 CD3 9 10 9 /l only between days 72 and 140 post-transplant (Eyrich et al, 2001 Lang et al, 2003) . It remains unclear whether the observed T cell recovery after SCB administration is due to peripheral expansion of co-transfused donor T cells (Mackall et al, 1996) or, more likely, to thymus-dependent de novo generation. After allogeneic stem cell transplantation thymic cellularity and function is restored by influx of committed progenitors and seeding of differentiation niches in the cortex. Current concepts apprehend this process as oscillating open and closed gates with a 21-day cyclic period (Goldschneider, 2006) . Thus, we hypothesize that CD34 + boosts may provide a thymic-seeding progenitor population with the ability to follow T-cell developmental pathways intrathymically (Donskoy & Goldschneider, 1992; Saran et al, 2010) . Indeed, Six et al (2007) described a lymphoid-restricted, lineage-negative CD34 + CD10 + CD24 À progenitor subset in human bone marrow and peripheral blood which has the capacity to repopulate the thymus and to differentiate into NK, B and T cells. We speculate that thymic T-cell regeneration may have been accelerated by the following factors: (i) SCBs were given at a time when conditioning-related thymic damage has probably already resolved (median: 94 days post-transplant); (ii) neither ATG nor post transplant immunosuppression was given and therefore, could not interfere with the lymphocyte reconstitution. Thus, it is conceivable that a later boost of CD34 + progenitors triggers another wave of thymic seeding with accelerated passage through the T-cell differentiation process. However, this hypothesis needs to be addressed in future studies. We observed a trend for better OS in patients with a CR to SCBs compared to patients who did not respond (Fig 5) . The high rate of relapse-related mortality in our cohort may have altered the composition of the evaluable cohort, preventing OS from reaching statistical significance. Post-HSCT stem cell boosting strategies other than CD34 + positive selection are currently under evaluation, i.e. CD3/CD19 and TcRab depletion, which allow the retention of important mature T cell populations, such as TcRcd and NK cells, known to play a role in underlying disease and infection control. There are few reports about the use of such techniques (R adestad et al, 2014) , and the indication for SCB is slightly different (poor immune reconstitution rather than PGF) but, together with our own findings, they suggest additional interactions between stem cells and already committed populations of precursors, which deserve further investigation. The present study has clear limitations due to its retrospective nature. Nevertheless it demonstrates that CD34 + positively-selected stem cell boosting is a reasonable and remarkably safe treatment option for patients with poor graft function, allowing the avoidance of any immunosuppression. Further studies are warranted to precisely evaluate the impact on immune reconstitution and survival.
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